Maintenance treatment after first chemotherapy for extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of extensive stage small cell lung cancer (cancer that has spread beyond the lung).
- You should be in reasonably good health, able to care for yourself (ECOG 0-2).
- You must not have had any prior chemotherapy or other systemic treatment for extensive stage SCLC.
- Your organs must be working well enough (adequate blood counts, liver, kidney, and blood clotting).
- You must not have symptomatic brain metastases or meningitis involvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
This study tests whether a combination of two targeted drugs can help keep extensive-stage small cell lung cancer from growing after initial treatment. The goal is to see if this maintenance approach extends the time before the cancer worsens.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.